Foghorn Therapeutics Inc. (FHTX) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 4.06 |
| Open | 4.05 |
| Day High | 4.22 |
| Day Low | 4.04 |
| 52-Week High | 6.95 |
| 52-Week Low | 3.27 |
| Volume | 120,851.24 |
| Average Volume | 158,574 |
| Market Cap | 243.96M |
| PE | -3.55 |
| EPS | -1.17 |
| Moving Average 50 Days | 4.48 |
| Moving Average 200 Days | 4.89 |
| Change | 0.1 |
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer
GlobeNewswire Inc.
Feb 23, 2026 12:00 PM GMT
WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today anno
Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit
GlobeNewswire Inc.
Feb 03, 2026 12:00 PM GMT
WATERTOWN, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today anno
Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium
GlobeNewswire Inc.
Jan 13, 2026 9:05 PM GMT
WATERTOWN, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today anno